BLOC-1 related complex subunit 8Genealiases: MEF2BNB · NDOABA
Q-omics provides the consensus-scored BORCS8 profile across patient tissues and cancer cell-line models. BORCS8 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, BORCS8 is differentially expressed in 15, with the highest sampling consensus in LIHC. Additionally, BORCS8 RNA expression shows 19,363 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UVM, and LIHC as cancer lineages where BORCS8 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for BORCS8 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes BORCS8 survival associations across molecular data types. BORCS8 RNA expression shows survival associations in the most cancer types (24), followed by mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible BORCS8 RNA expression–survival associations across cancer types. High BORCS8 expression shows unfavorable associations in UVM, ACC, SKCM, KICH and LGG, but favorable associations in PAAD. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for BORCS8 RNA expression.
This table summarizes BORCS8 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 4. The strongest signals are observed in LIHC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for BORCS8. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. BORCS8 shows lower tumor expression in KICH, THCA and LUAD and higher tumor expression in LIHC, HNSC and UCEC. The LIHC box plot shows higher BORCS8 RNA expression in tumor versus normal tissue (log2 FC = +1.402, t-test p < 0.001).
This table shows molecular features associated with BORCS8 in patient tissues and cancer cell lines. In patient samples, BORCS8 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, BORCS8 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and BLOOD_Lymphoma.
